Despite a rough ride on the capital markets, particularly in the second half of the year, the biopharmaceutical sector had no difficulty in attracting capital. According to BioWorld data, the $67.1 billion that was raised by global companies from public and private sources in 2018 was just shy of the leading total of $68.4 billion generated in 2015 and places it firmly in second place in terms of totals raised in the history of the industry.